Selective Minimally Invasive Treatment of Solid Tumors
Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
CAPS Medical is a medical device company focused on the development and commercialization of its NTAP System, which uses non-thermal atmospheric plasma (NTAP) to treat a wide range of solid tumors. The minimally invasive and selective cancer treatment targets solid tumors and aims to selectively and precisely destroy only cancerous cells, leaving healthy tissue intact.
The company has demonstrated the safety and efficacy of the technology in animal studies and is nearing clinical application. Its first area of focus is non-muscle invasive bladder cancer (NMIBC). The system will then go on to address a wide range of solid tumors found in lung, liver, breast, gastrointestinal, and other cancers, for which it is on track to make a profound and needed impact.
Originally developed at the Technion - Israel Institute of Technology, the system is supported by key opinion leaders from medical fields such as oncology and interventional radiology. CAPS Medical has been supported by major shareholders Boston Scientific and MEDX Ventures Group.